Mechanisms of Androgen Receptor Activation in Castration-resistant Prostate Cancer

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2013 Sep 5

PMID 24002034

Citations 52

Authors

Nima Sharifi

Affiliations

Soon will be listed here.

Abstract

Systemic treatment of advanced prostate cancer is initiated with androgen deprivation therapy by gonadal testosterone depletion. Response durations are variable and tumors nearly always become resistant as castration-resistant prostate cancer (CRPC), which is driven, at least in part, by a continued dependence on the androgen receptor (AR). The proposed mechanisms that underlie AR function in this clinical setting are quite varied. These include intratumoral synthesis of androgens from inactive precursors, increased AR expression, AR activation through tyrosine kinase-dependent signaling, alterations in steroid receptor coactivators, and expression of a truncated AR with constitutive activity. Various pharmacologic interventions have clinically validated some of these mechanisms, such as those that require the AR ligand-binding domain. Clinical studies have failed to validate other mechanisms, and additional mechanisms have yet to be tested in patients with CRPC. Here, we review the mechanisms that elicit AR activity in CRPC, with a particular focus on recent developments.

Citing Articles

Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.

Mokhosoev I, Astakhov D, Terentiev A, Moldogazieva N Cells. 2024; 13(23).

PMID: 39682707 PMC: 11639897. DOI: 10.3390/cells13231958.

Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.

Wang J, Liu H, Yu Z, Zhou Q, Sun F, Han J Cell Commun Signal. 2024; 22(1):339.

PMID: 38898473 PMC: 11186203. DOI: 10.1186/s12964-024-01703-w.

MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer.

Khatiwada P, Rimal U, Han Z, Shemshedini L Endocr Oncol. 2024; 4(1):e230017.

PMID: 38410785 PMC: 10895308. DOI: 10.1530/EO-23-0017.

Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.

Pimenta R, Malulf F, Romao P, Caetano G, da Silva K, Ghazarian V J Cancer Res Clin Oncol. 2024; 150(2):70.

PMID: 38305916 PMC: 10837222. DOI: 10.1007/s00432-023-05598-x.

Targeting sex steroid biosynthesis for breast and prostate cancer therapy.

Poutanen M, Hagberg Thulin M, Harkonen P Nat Rev Cancer. 2023; .

PMID: 37684402 DOI: 10.1038/s41568-023-00609-y.

References

Simard J, Ricketts M, Gingras S, Soucy P, Feltus F, Melner M . Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev. 2005; 26(4):525-82. DOI: 10.1210/er.2002-0050. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Veldscholte J, Ris-Stalpers C, Kuiper G, Jenster G, Berrevoets C, Claassen E . A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990; 173(2):534-40. DOI: 10.1016/s0006-291x(05)80067-1. View

Liu L, Xie N, Sun S, Plymate S, Mostaghel E, Dong X . Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2013; 33(24):3140-50. PMC: 4553036. DOI: 10.1038/onc.2013.284. View

Bruchovsky N, Wilson J . The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem. 1968; 243(22):5953-60. View

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Knudsen K, Penning T . Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010; 21(5):315-24. PMC: 2862880. DOI: 10.1016/j.tem.2010.01.002. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Ponguta L, Gregory C, French F, Wilson E . Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem. 2008; 283(30):20989-1001. PMC: 2475695. DOI: 10.1074/jbc.M802392200. View

10.

Gelmann E . Molecular biology of the androgen receptor. J Clin Oncol. 2002; 20(13):3001-15. DOI: 10.1200/JCO.2002.10.018. View

11.

Andersson S, Russell D, Wilson J . 17beta-Hydroxysteroid dehydrogenase 3 deficiency. Trends Endocrinol Metab. 1996; 7(4):121-6. DOI: 10.1016/1043-2760(96)00034-3. View

12.

Dean J, Sprenger C, Wan J, Haugk K, Ellis W, Lin D . Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013; 98(5):E820-8. PMC: 4430583. DOI: 10.1210/jc.2012-3856. View

13.

Geng C, He B, Xu L, Barbieri C, Eedunuri V, Chew S . Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013; 110(17):6997-7002. PMC: 3637757. DOI: 10.1073/pnas.1304502110. View

14.

Evaul K, Li R, Papari-Zareei M, Auchus R, Sharifi N . 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010; 151(8):3514-20. DOI: 10.1210/en.2010-0138. View

15.

Li Y, Alsagabi M, Fan D, Bova G, Tewfik A, Dehm S . Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011; 71(6):2108-17. PMC: 3059379. DOI: 10.1158/0008-5472.CAN-10-1998. View

16.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

17.

Gottlieb B, Beitel L, Wu J, Trifiro M . The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat. 2004; 23(6):527-33. DOI: 10.1002/humu.20044. View

18.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

19.

Bruchovsky N, Wilson J . The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem. 1968; 243(8):2012-21. View

20.

Thigpen A, Cala K, Russell D . Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. J Biol Chem. 1993; 268(23):17404-12. View